Quest Products LLC Launches a Nasal Filter Device that Blocks Microscopic Airborne Particles and Pollutants

Quest Products, LLC introduces a new nasal filter designed for people interested in protection against the smallest of airborne particles and pollutants.

Its unique filtration material is electrostatically charged to better capture microscopic particles and protect people from droplets released during coughing and sneezing. In a study by LMS Technologies, the new breatheWELL Nasal Filter was proven as a unique barrier against airborne particles measuring as small as 3 microns. In fact, the study demonstrated a 90 percent effectiveness against particles measuring 10 microns and 60 percent effectiveness against particles measuring 2.5 microns—this is within the micron measurement range of the smallest sized bacteria, pollen and allergen. According to the results of the study, the nasal filters can block up to 99% of airborne particles and pollutants.

“In recent news reports, immunology and allergy specialists encourage people to do all they can to alleviate inflammation to the lungs caused by breathing in common allergens because it may leave them more susceptible to respiratory illnesses,” said Jon Romanow, Director of Marketing, Quest Products, LLC. “We believe that our new product will be helpful to people seeking additional options to protect their overall health by blocking the inhalation of pollens, pollutants and bacteria that reach the lungs through the nose. These filters are ideal for protection during travel when around pets or while working in dusty environments.”

The unique filtration material makes breatheWELL™ a reliable option for reducing direct and indirect airborne transmission of unwanted particles breatheWELL™ nasal filters fit discreetly into the front of the nostrils. It is drug-free, latex-free and the rings are made of a surgical-grade polymer that is non-toxic.

breatheWELL™ is available now for purchase online at Amazon and at breatheandsleepwell.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version